ライフサイエンスコーパス: thyrotropin

1 ituitary hormones follitropin, lutropin, and thyrotropin.

2 have mild compensated thyroid resistance to thyrotropin action, not subclinical autoimmune primary h

3 These deficiencies include growth hormone, thyrotropin, adrenocorticotropin and gonadotropin defici

4 lts were found for low-dose radioiodine plus thyrotropin alfa (84.3%) versus high-dose radioiodine pl

5 drawal (87.6%) or high-dose radioiodine plus thyrotropin alfa (90.2%).

6 the high-dose group (P=0.007) and 23% in the thyrotropin alfa group versus 30% in the group undergoin

7 oup receiving the high dose and 87.1% in the thyrotropin alfa group versus 86.7% in the group undergo

8 radioiodine, each in combination with either thyrotropin alfa or thyroid hormone withdrawal before ab

9 Low-dose radioiodine plus thyrotropin alfa was as effective as high-dose radioiodi

10 using either recombinant human thyrotropin (thyrotropin alfa) or thyroid hormone withdrawal.

11 After stimulation with thyrotropin alfa, dosimetry with iodine-124 positron-emi

12 ss provided blood samples for measurement of thyrotropin and free thyroxine (T(4)).

13 Thyrotropin and free thyroxine should be measured and, w

14 nfirmed or excluded by measurements of serum thyrotropin and free thyroxine.

15 The use of recombinant human thyrotropin and low-dose (1.1 GBq) postoperative radioio

16 lites were largely inversely associated with thyrotropin and positively associated with free and tota

17 erum concentrations of the pituitary hormone thyrotropin and the thyroid hormones thyroxine and triio

18 l hypothyroidism (characterized by low serum thyrotropin and thyroxine concentrations) in a patient w

19 e divergence of lutropins, follitropins, and thyrotropins and the speciation of teleost fish may have

20 mone withdrawal and use of recombinant human thyrotropin) and two radioiodine ((131)I) doses (i.e., a

21 s a result of abnormal central regulation of thyrotropin, and also develop profound hearing loss.

22 d subacute thyroiditis, tumours that secrete thyrotropin, and drug-induced thyroid dysfunction, are a

23 ent on the pituitary hormones lutropin (LH), thyrotropin, and pro-opiomelanocortin.

24 h occasion, serum thyroxine, free thyroxine, thyrotropin, and thyroxine-binding globulin were measure

25 le for thyroid-stimulating hormone (TSH; ie, thyrotropin) as an inductive signal for tumor necrosis f

26 The introduction of sensitive thyrotropin assays and free thyroid hormone measurements

27 The action of thyrotropin at the thyroid cell was assessed as a growth

28 glycoprotein hormone subunit (alpha-GSU) and thyrotropin beta subunit (TSH-beta) genes is stimulated

29 vitro, LGD346 suppressed the activity of the thyrotropin beta-subunit gene promoter in thyrotrophs by

30 lective ligand LGD346 on the activity of the thyrotropin beta-subunit gene promoter.

31 of the growth hormone, prolactin (PRL), and thyrotropin-beta genes.

32 A-subunit adenovirus developed TSHR Abs with thyrotropin-binding inhibitory activity, although at low

33 nutes during the night of sleep deprivation, thyrotropin bioactivity, the thyrotropin response to pro

34 ypothesized and confirmed that TSAb (but not thyrotropin-blocking autoantibodies [TBAb's]) also poorl

35 /=18 years) who had at least two creatinine, thyrotropin, calcium, glycated haemoglobin, or lithium m

36 levothyroxine was increased to maintain the thyrotropin concentration at preconception values throug

37 The mean serum thyrotropin concentration declined from 2.2 mU per liter

38 /-4 pmol per liter, P<0.001) and their serum thyrotropin concentration increased from 0.9+/-1.1 to 3.

39 the fully rested condition (p<0.02), as were thyrotropin concentrations (p<0.01).

40 We then located 47 women with serum thyrotropin concentrations at or above the 99.7th percen

41 yroid function, the serum free thyroxine and thyrotropin concentrations did not change, whereas at 12

42 The serum thyrotropin concentrations increased to more than 7 micr

43 were no significant differences in neonatal thyrotropin concentrations of heel samples between mothe

44 Mean (95% CI) thyrotropin concentrations of neonates born to mothers w

45 The children of the 62 women with high serum thyrotropin concentrations performed slightly less well

46 Nocturnal serum thyrotropin concentrations were consistently higher in r

47 median maternal urinary iodine and neonatal thyrotropin concentrations, along with other relevant da

48 ary hormones lutropin (LH), follitropin, and thyrotropin constitute the family of glycoprotein hormon

49 Thyrotropin-dependent cell growth and DNA synthesis were

50 00E) did not induce growth in the absence of thyrotropin despite increasing DNA synthesis, which is l

51 Advances related to thyrotropin during 1999 included better understanding of

52 We measured serum thyrotropin every 15 minutes during the night of sleep d

53 We propose that if assays for thyrotropin, free T3, and free T4 are all done, knowledg

54 Maternal thyroid hormone levels (thyrotropin, free thyroxine, thyroid peroxidase antibodi

55 ones, like thyroid-stimulating hormone (TSH; thyrotropin), have only recently been reported, and none

56 iogonadotropin, human follitropin, and human thyrotropin heterodimers occurs in this fashion, indicat

57 To gain insight into the thyrotropin hormone (TSH) receptor (TSHR) cleavage, we s

58 eered the first superactive analogs of human thyrotropin (hTSH) by using a novel design strategy.

59 serum thyroid hormones and suppressed serum thyrotropin in almost all cases.

60 ly postpartum period; however, the values of thyrotropin in cord samples of neonates born to mothers

61 Initial clinical use of recombinant thyrotropin in evaluation of thyroid cancer recurrence w

62 A single measurement of low serum thyrotropin in individuals aged 60 years or older is ass

63 The bioactivity of thyrotropin in nonresponders was significantly greater t

64 , compared with heel blood samples, neonatal thyrotropin in samples collected from the cord are more

65 We measured concentration of thyrotropin in serum at baseline in 1988-89.

66 In 1996 and 1997, we measured thyrotropin in stored serum samples collected from 25,21

67 ma T3 and an "inappropriately normal" plasma thyrotropin in the absence of intrinsic disease of the h

68 Low serum thyrotropin, in combination with normal concentrations o

69 on; its level in the thyroid is regulated by thyrotropin-increased cyclic AMP levels.

70 aminotriazole, in which increased release of thyrotropin induces massive colloid endocytosis.

71 nd for hypothyroxinemia, defined as a normal thyrotropin level (0.08 to 3.99 mU per liter) and a low

72 t was adjusted as needed to achieve a target thyrotropin level of 0.1 to 1.0 mIU per liter.

73 for subclinical hypothyroidism, defined as a thyrotropin level of 4.00 mU or more per liter and a nor

74 The mean (+/-SD) thyrotropin level was 6.40+/-2.01 mIU per liter at basel

75 o had persisting subclinical hypothyroidism (thyrotropin level, 4.60 to 19.99 mIU per liter; free thy

76 ease), with dose adjustment according to the thyrotropin level; 369 patients were assigned to receive

77 roid-stimulating hormone (TSH; also known as thyrotropin) level and these outcome parameters.

78 Thyrotropin levels above the 97.5th percentile, free T(4

79 Serum thyrotropin levels remained similar and within the norma

80 Thereafter, serum thyrotropin levels should be monitored and the levothyro

81 s, and that switching back to tablets caused thyrotropin levels to worsen, leads us to believe that a

82 of free thyroxine coexisting with reference thyrotropin levels, and children's symptoms of ADHD.

83 raphic factors, systemic medical conditions, thyrotropin levels, and medical and surgical interventio

84 ality within the cohort according to initial thyrotropin measurement.

85 hyrotropin-releasing hormone in synthesis of thyrotropin molecules with mature glycosylation, and the

86 er first measurement in those with low serum thyrotropin (n471).

87 yroxine dose was adjusted to attain a normal thyrotropin or free T4 level (depending on the trial), w

88 No change in levels of serum thyrotropin or triiodothyronine was detected, although t

89 pled receptors with dissociable agonists for thyrotropin, parathyroid hormone, and sphingosine-1-phos

90 eptor staining was visible in prolactin- and thyrotropin-producing cells in rat pituitary tissue from

91 that such ligands could reversibly suppress thyrotropin production by a thyroid hormone-independent

92 xpressing either mouse (mM12 cells) or human thyrotropin receptor (TSHR) (hM12 cells).

93 Thyrotropin receptor (TSHR) Ab's of the stimulating vari

94 es' disease (GD), autoantibodies bind to the thyrotropin receptor (TSHR) and cause hyperthyroidism.

95 vity of AAbeta1AR and AAM2R with stimulating thyrotropin receptor (TSHR) antibodies was evaluated bef

96 We studied cell surface thyrotropin receptor (TSHR) by biotinylating proteins on

97 the glycoprotein hormone receptors, only the thyrotropin receptor (TSHR) cleaves (at two sites) into

98 between the cysteine-rich N terminus of the thyrotropin receptor (TSHR) ectodomain and epidermal gro

99 s, the detection of circulating DTC cells by thyrotropin receptor (TSHR) mRNA measurement distinguish

100 g mutations are, however, more common in the thyrotropin receptor (TSHR) than in its downstream trans

101 Abs that stimulate the thyrotropin receptor (TSHR), the cause of Graves' hypert

102 The thyrotropin receptor (TSHR), the major autoantigen in Gr

103 y caused by autoantibodies that activate the thyrotropin receptor (TSHR).

104 ng autoantibodies (TSAb's) that activate the thyrotropin receptor (TSHR).

105 yroid-stimulating Abs (TSAbs) activating the thyrotropin receptor (TSHR).

106 Activating anti-thyrotropin receptor Abs are responsible for hyperthyroi

107 of patients developed antibodies against the thyrotropin receptor and carbimazole-responsive autoimmu

108 activation of shared autoantigens including thyrotropin receptor and insulin-like growth factor-1 re

109 Thyrotropin receptor antigen on fibroblasts diffusely in

110 responsiveness associated with inhibition of thyrotropin receptor gene expression.

111 odide symporter, thyroid peroxidase, TG, and thyrotropin receptor genes.

112 elix scaffold, which endowed the substituted thyrotropin receptor intracellular domain elements with

113 ies of glycoprotein hormone receptors (e.g., thyrotropin receptor) and biogenic amine receptors (e.g.

114 The thyrotropin receptor, also known as the thyroid-stimulat

115 ss a point mutation in the gene encoding the thyrotropin receptor, and affected animals are congenita

116 ot impair key activation steps distal to the thyrotropin receptor, such as forskolin-induced adenylyl

117 ) B cells produce pathogenic Abs against the thyrotropin receptor.

118 he intracellular domain of a model GPCR, the thyrotropin receptor.

119 nction and gain-of-function mutations of the thyrotropin receptor.

120 sembled models of lutropin, follitropin, and thyrotropin receptors by aligning models of their LRD, T

121 xplains how substitutions in follitropin and thyrotropin receptors distant from their apparent ligand

122 led receptors homologous to gonadotropin and thyrotropin receptors have recently been identified and

123 distinguish lutropin (LHR), follitropin, and thyrotropin receptors.

124 The rat prepro-thyrotropin releasing hormone (TRH) 178-199 is derived f

125 y cooperative interaction between leptin and thyrotropin releasing hormone (TRH) in the hindbrain to

126 istry and RT-PCR demonstrated a reduction of Thyrotropin Releasing Hormone (TRH) in the hypothalamus

127 The biogenesis of rat thyrotropin releasing hormone (TRH) involves the process

128 gene expression of Sim1, oxytocin (OXT) and thyrotropin releasing hormone (TRH) was reduced by about

129 ith the calcium ionophore ionomycin, or with thyrotropin releasing hormone or vasoactive intestinal p

130 r neurotransmitters such as glutamate, GABA, thyrotropin releasing hormone, and substance P encoded b

131 he nonhydrolysable cAMP analog 8-bromo-cAMP, thyrotropin releasing hormone, or cholecystokinin reveal

132 ysis showed that proteolytic cleavage of pro-thyrotropin-releasing hormone (proTRH) at known PC cleav

133 of 5-hydroxytryptamine (serotonin, 5-HT) and thyrotropin-releasing hormone (TRH) act synergistically

134 n-Leu-Pro-Gly, a progenitor sequence for the thyrotropin-releasing hormone (TRH) analogue [Leu(2)]TRH

135 Metabolically stable and centrally acting thyrotropin-releasing hormone (TRH) analogues were desig

136 has an important action on hypophysiotropic thyrotropin-releasing hormone (TRH) and corticotropin-re

137 cifically from subsets of neurons expressing thyrotropin-releasing hormone (TRH) and pituitary adenyl

138 nism of trans-repression of the hypothalamic thyrotropin-releasing hormone (TRH) and pituitary thyroi

139 y and pontine raphe and receives inputs from thyrotropin-releasing hormone (TRH) and substance P-expr

140 pituitary-thyroid (HPT) axis hormones, i.e., thyrotropin-releasing hormone (TRH) and thyrotropin (TSH

141 We show that several analogs of thyrotropin-releasing hormone (TRH) are more efficacious

142 To test whether pro-thyrotropin-releasing hormone (TRH) conversion to TRH in

143 Hypothalamic T3 content is decreased while thyrotropin-releasing hormone (TRH) expression is elevat

144 daptive response is caused by a reduction in thyrotropin-releasing hormone (TRH) expression that can

145 y marginally elevated in transgenic mice and thyrotropin-releasing hormone (TRH) gene expression in t

146 Thyrotropin-releasing hormone (TRH) has previously been

147 y predicting the structure of the tripeptide thyrotropin-releasing hormone (TRH) in solution.

148 ve feedback loop that inhibits production of thyrotropin-releasing hormone (TRH) in the mediobasal hy

149 Thyrotropin-releasing hormone (TRH) increases activity a

150 nin) enhanced GIRK channel currents, whereas thyrotropin-releasing hormone (TRH) inhibited both basal

151 The hypothalamic neuropeptide, thyrotropin-releasing hormone (TRH) inhibits ERG channel

152 In vertebrates thyrotropin-releasing hormone (TRH) is a highly conserve

153 Thyrotropin-releasing hormone (TRH) is a tripeptide that

154 The neuropeptide thyrotropin-releasing hormone (TRH) is recognized to pla

155 Thyrotropin-releasing hormone (TRH) is reported to have

156 in the DMH and in the posterior Pe coexpress thyrotropin-releasing hormone (TRH) mRNA.

157 ed in fibers that innervate hypophysiotropic thyrotropin-releasing hormone (TRH) neurons and modulate

158 nal and cellular effects of the neuropeptide thyrotropin-releasing hormone (TRH) on the spontaneously

159 Basal [Ca(2+)](cyt) was about 50 nm; thyrotropin-releasing hormone (TRH) or other agonists in

160 jection of peptide YY (PYY) and low doses of thyrotropin-releasing hormone (TRH) or TRH analog, RX 77

161 Raphe-derived serotonin (5-HT) and thyrotropin-releasing hormone (TRH) play important roles

162 ly that left ventricular gene expression for thyrotropin-releasing hormone (TRH) precursor was increa

163 ryptophan and other aromatic residues of the thyrotropin-releasing hormone (TRH) receptor (TRH-R) tha

164 k, a model of the extracellular loops of the thyrotropin-releasing hormone (TRH) receptor (TRHR) was

165 The G protein-coupled thyrotropin-releasing hormone (TRH) receptor is phosphor

166 smembrane helices 5 and 6 (TMH5 and TMH6) of thyrotropin-releasing hormone (TRH) receptor type I (TRH

167 The thyrotropin-releasing hormone (TRH) receptor undergoes r

168 The thyrotropin-releasing hormone (TRH) receptor was express

169 HEK293 cells expressing the thyrotropin-releasing hormone (TRH) receptor were transf

170 We tested whether thyrotropin-releasing hormone (TRH) receptors lacking ph

171 Dimerization and phosphorylation of thyrotropin-releasing hormone (TRH) receptors was charac

172 Here we show that mouse thyrotropin-releasing hormone (TRH) receptors, subtypes

173 Hypothalamic thyrotropin-releasing hormone (TRH) stimulates thyroid-s

174 feedback inhibition of thyrotropin (TSH) and thyrotropin-releasing hormone (TRH) synthesis in the pit

175 Thyrotropin-releasing hormone (TRH) synthesized in medul

176 Galanin, gamma-aminobutyric acid (GABA), and thyrotropin-releasing hormone (TRH) were colocalized wit

177 A binding pocket for thyrotropin-releasing hormone (TRH) within the transmemb

178 the activity of orexin cells is modulated by thyrotropin-releasing hormone (TRH), an endogenous stimu

179 cretin, melanin-concentrating hormone (MCH), thyrotropin-releasing hormone (TRH), gonadotropin-releas

180 Thyrotropin-releasing hormone (TRH), like most small lig

181 ear ER-alpha ir was found in a population of thyrotropin-releasing hormone (TRH)-expressing neurons i

182 beta-Arrestin 2 reduced thyrotropin-releasing hormone (TRH)-stimulated inositol

183 center for the central actions of leptin on thyrotropin-releasing hormone (TRH)-synthesizing neurons

184 lved in the control of thermogenesis such as thyrotropin-releasing hormone (TRH).

185 gulation of several neuropeptides, including thyrotropin-releasing hormone (TRH).

186 ta subunit (TSH-beta) genes is stimulated by thyrotropin-releasing hormone (TRH).

187 and inhibitory modulation of K+ channels by thyrotropin-releasing hormone (TRH).

188 urrent was not sensitive to glibenclamide or thyrotropin-releasing hormone (TRH).

189 dose: 100 nM), compared to that observed for thyrotropin-releasing hormone (TRH, minimum effective do

190 We and others have previously reported that thyrotropin-releasing hormone (TRH, pGlu-His-Pro-NH(2))

191 Thyrotropin-releasing hormone (TRH; Protirelin) is an en

192 Thyrotropin-releasing hormone (TRH; protirelin), a brain

193 y cooperative interaction between leptin and thyrotropin-releasing hormone [TRH] to activate hindbrai

194 y cooperative interaction between leptin and thyrotropin-releasing hormone [TRH] to activate hindbrai

195 hormone, corticotropin-releasing factor, and thyrotropin-releasing hormone also stimulated calcium si

196 omatostatin, corticotropin-releasing factor, thyrotropin-releasing hormone and calcitonin gene-relate

197 express corticotrophin-releasing hormone or thyrotropin-releasing hormone and do not express arginin

198 or lung disease, antenatal administration of thyrotropin-releasing hormone and glucocorticoid is no m

199 expression was found in PVH cells producing thyrotropin-releasing hormone and in cholinergic DMV cel

200 that CG5911 is evolutionarily related to the thyrotropin-releasing hormone and neuromedin U receptors

201 Some thyrotropin-releasing hormone and neurotensin neurons we

202 ng juvenile chum salmon (Oncorhynchus keta), thyrotropin-releasing hormone gene expression increased

203 uld mediate the effect of glucocorticoids on thyrotropin-releasing hormone gene expression.

204 ytocin, corticotropin-releasing hormone, and thyrotropin-releasing hormone in an appropriate spatial

205 regulating the effect of glucocorticoids on thyrotropin-releasing hormone in fetal rat diencephalic

206 pattern was clarified including the role of thyrotropin-releasing hormone in synthesis of thyrotropi

207 le metabolism, regulation of food intake, or thyrotropin-releasing hormone levels in the hypothalamus

208 hysiotropic PVH cells coexpress Y1-R and pro-thyrotropin-releasing hormone mRNAs in the rat.

209 The existence of c-fos/c-jun in thyrotropin-releasing hormone neurons and the increased

210 The latter is also influenced by thyrotropin-releasing hormone neurons that act centrally

211 ral preoptic nucleus, and a mainly glutamate-thyrotropin-releasing hormone projection to the wake-pro

212 rmore, IGSF1 stimulates transcription of the thyrotropin-releasing hormone receptor (TRHR) by negativ

213 DSGCs: dopamine receptor 4 (DRD4)-DSGCs and thyrotropin-releasing hormone receptor (TRHR)-DSGCs.

214 93 cells co-expressing TREK-1 and either the thyrotropin-releasing hormone receptor (TRHR1) or the Or

215 In contrast, the mammalian thyrotropin-releasing hormone receptor and the African c

216 udy phosphorylation of the endogenous type I thyrotropin-releasing hormone receptor in the anterior p

217 the C-terminal tail of either the mammalian thyrotropin-releasing hormone receptor or the catfish Gn

218 Thyrotropin-releasing hormone receptor type 2 (TRH-R2),

219 tion-selective ganglion cells (dsGCs): TRHR (thyrotropin-releasing hormone receptor) and Drd4 (dopami

220 otensin receptor 1, vasopressin V2 receptor, thyrotropin-releasing hormone receptor, and substance P

221 five structurally diverse antagonists of the thyrotropin-releasing hormone receptors (TRH-R1 and TRH-

222 The addition of antenatal thyrotropin-releasing hormone therapy has been reported

223 lex and includes suppression of hypothalamic thyrotropin-releasing hormone, accounting for persistent

224 d by serotonin, norepinephrine, substance P, thyrotropin-releasing hormone, and 3,5-dihydroxyphenylgl

225 n-releasing hormone, oxytocin, somatostatin, thyrotropin-releasing hormone, and vasopressin.

226 than another inducer of prolactin secretion, thyrotropin-releasing hormone, both in vitro and in vivo

227 onadotropin-releasing hormone, somatostatin, thyrotropin-releasing hormone, corticotropin-releasing h

228 by the expression of oxytocin, vasopressin, thyrotropin-releasing hormone, corticotropin-releasing h

229 bo-controlled, randomized trial of antenatal thyrotropin-releasing hormone, given intravenously in fo

230 with chronic ECS such as neuropeptide Y and thyrotropin-releasing hormone, may provide novel ways to

231 modulation of RTN activity by Substance P or thyrotropin-releasing hormone, previously identified neu

232 rvicellular corticotropin-releasing hormone, thyrotropin-releasing hormone, somatostatin, and dopamin

233 In neuroD2-deficient mice, thyrotropin-releasing hormone, thyroid-stimulating hormo

234 f these channels also disrupted transmitter (thyrotropin-releasing hormone, TRH) inhibition and did s

235 including corticotropin-releasing hormone-, thyrotropin-releasing hormone-, vasopressin-, and oxytoc

236 eport of diurnal variations in the levels of thyrotropin-releasing hormone-like peptides (pGlu-X-Pro-

237 in, corticotropin-releasing hormone (CRH) or thyrotropin-releasing hormone.

238 estphal nucleus was identified as containing thyrotropin-releasing hormone.

239 ted responses to leptin and a suppression of thyrotropin-releasing hormone.

240 thyroid-stimulating hormone and hypothalamic thyrotropin-releasing hormone.

241 ated by food availability via leptin-induced thyrotropin-releasing hormone/thyroid-stimulating hormon

242 ep deprivation, thyrotropin bioactivity, the thyrotropin response to protirelin the next afternoon, a

243 reduced by BRAF(V600E) because of decreased thyrotropin responsiveness associated with inhibition of

244 ecretion were evaluated, including pituitary thyrotropin-secreting adenomas.

245 of hyperthyroidism, including struma ovarii, thyrotropin-secreting tumours, choriocarcinoma, and amio

246 The degree of suppression of thyrotropin secretion tended to be greater in patients t

247 Causes of excessive thyrotropin secretion were evaluated, including pituitar

248 inoid X receptor-selective ligand suppresses thyrotropin secretion.

249 own significantly increased isoproterenol or thyrotropin-stimulated cAMP accumulation.

250 ography and measurement of recombinant human thyrotropin-stimulated thyroglobulin.

251 r randomized, phase 3 trial, we compared two thyrotropin-stimulation methods (thyroid hormone withdra

252 ent between the (131)I doses and between the thyrotropin-stimulation methods.

253 concentrations of T3 but not T4 can suppress thyrotropin subunit beta gene expression.

254 Goiter development due to incomplete thyrotropin suppression, a thyroidal radioiodide uptake

255 on, use of radioactive iodine, and degree of thyrotropin suppression.

256 oU per milliliter in 3 of the 7 women in the thyrotropin-suppression group.

257 ne-replacement therapy and 7 women receiving thyrotropin-suppressive thyroxine therapy.

258 s 2-5 were higher in patients with low serum thyrotropin than in the rest of the cohort (hazard ratio

259 light of the contemporary use of recombinant thyrotropin (thyroid-stimulating hormone) (rTSH) to prep

260 ted thyroid hormone levels and inappropriate thyrotropin (thyroid-stimulating hormone, or TSH) produc

261 The thyrotropin [thyroid-stimulating hormone (TSH)] receptor

262 Evidence was presented that thyrotropin [thyroid-stimulating hormone (TSH)]-stimulat

263 influenced by using either recombinant human thyrotropin (thyrotropin alfa) or thyroid hormone withdr

264 Thyrotropin (TSH) activation of the TSH receptor (TSHR),

265 Here, for the heritable thyroid traits thyrotropin (TSH) and free thyroxine (FT4), we analyse w

266 ction is regulated by feedback inhibition of thyrotropin (TSH) and thyrotropin-releasing hormone (TRH

267 When elevated thyrotropin (TSH) and/or decreased T4 are found in the b

268 provided that the bioactivity and action of thyrotropin (TSH) are not impaired.

269 Wistar rat thyroid cells are dependent upon thyrotropin (TSH) for growth.

270 autoimmune gastritis, who showed high serum thyrotropin (TSH) levels (in the hypothyroid range) whil

271 had a 3.4-fold (p < 0.02) increase in serum thyrotropin (TSH) levels.

272 AMP is a critical mediator of the effects of thyrotropin (TSH) on cell proliferation and differentiat

273 Thyrotropin (TSH) receptor (TSHR) A and B subunits are f

274 The thyrotropin (TSH) receptor (TSHR) is a member of the het

275 e caused by pathogenic autoantibodies to the thyrotropin (TSH) receptor (TSHR), can be treated but no

276 To examine thyrotropin (TSH) receptor homophilic interactions we fu

277 COIP), we previously reported that the human thyrotropin (TSH) receptor tagged with green fluorescent

278 cently been associated with mutations in the thyrotropin (TSH) receptor, the cause of thyroid agenesi

279 antigen [particularly thyroid peroxidase and thyrotropin (TSH) receptor] and of high affinity monoclo

280 Thyrotropin (TSH) regulates thyroid cell proliferation a

281 In rat thyroid cells, thyrotropin (TSH) stimulates proliferation through a cAM

282 ransient accumulation of intracellular cAMP, thyrotropin (TSH) stimulation of the FRTL-5 thyroid cell

283 s triiodothyronine (T3), thyroxine (T4), and thyrotropin (TSH) were measured in plasma for 4 mo befor

284 hysiologically relevant system that requires thyrotropin (TSH), acting via cAMP, for a full mitogenic

285 .e., thyrotropin-releasing hormone (TRH) and thyrotropin (TSH), are expressed in human hair follicles

286 ne that controls thyroid hormone production, thyrotropin (TSH), caught the attention of skin research

287 Human thyrotropin (TSH), luteotropin (LH), follitropin (FSH),

288 rotein hormones chorionic gonadotropin (CG), thyrotropin (TSH), lutropin (LH), and follitropin (FSH)

289 elevation of thyroid-stimulating hormone, or thyrotropin (TSH), that occurs with hypothyroidism stimu

290 ittle is known about the mechanisms by which thyrotropin (TSH), the main hormonal regulator of thyroi

291 Thyrotropin (TSH), the physiologic regulator of thyroid

292 The G protein-coupled thyrotropin (TSH)-releasing hormone (TRH) receptor forms

293 tudies given the predominant role of cAMP in thyrotropin (TSH)-stimulated proliferation and as an onc

294 7.9), maternal thyroid function tests (serum thyrotropin [TSH], free thyroxine [fT4], and thyroid per

295 combinant human thyroid-stimulating hormone (thyrotropin; TSH) over the past 2 y.

296 the secretion of T4 induced by injection of thyrotropin was reduced in Mct8-KO in which endogenous T

297 DW/J-Pou1f1dw/dw mutant mice lack pituitary thyrotropin, which causes severe thyroid hormone deficie

298 ) of the pituitary, regulating expression of thyrotropin, which then relays messages back to the hypo

299 ivity; nonresponders compensate by secreting thyrotropin with increased bioactivity.

300 tion responders compensate by secreting more thyrotropin with normal bioactivity; nonresponders compe